Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

Please enter the email address for your account. A verification code will be sent to you. Once you have received the verification code, you will be able to choose a new password for your account.

THERANEXUS announces the clinical results of its phase 1b study demonstrating the extended pharmacological profile of its drug candidate THN201 compared to donepezil

15/01/2020
Download PDF File (381 Ko)

THERANEXUS and Beyond Batten Disease Foundation (BBDF) announce the signing of a worldwide exclusive license for Batten disease drug candidate BBDF-101

12/12/2019
Download PDF File (363 Ko)

THERANEXUS reports cash position as of September 30th 2019

15/10/2019
Download PDF File (285 Ko)

THERANEXUS announces its first half 2019 results

26/09/2019
Download PDF File (285 Ko)

A new milestone reached for Theranexus: inclusion of last patient in phase II trial for THN102 in Parkinson’s patients

24/09/2019
Download PDF File (285 Ko)